Consistent with these findings, The Cancer Genome Atlas (TCGA) analysis showed that patients with high-grade GBM exhibited significantly higher levels of STC2 mRNA than patients with low-grade glioma (Fig. 1c). This evidence concerns the gene STC2 and central nervous system cancer.